$ASTRAZEN : Driving Oncology Growth Through Innovation

📈 Analysts say $ASTRAZEN showcased robust momentum with a 36% YoY revenue surge in Q1 FY26, powered by four new oncology drug approvals. 🔑 Key highlight: Expanded CDSCO clearance for Imfinzi as a frontline treatment in endometrial cancer is a significant step, reinforcing its oncology leadership. 💰 The company is also making strides in digital health, investing ₹166 crore in an AI-driven global innovation hub aimed at transforming treatment platforms. 🚦 However, valuations remain elevated at around 118× PE, suggesting cautious optimism as the company balances innovation with market expectations. (Views as per recent research reports)